Target ALS is a non-profit medical research foundation relentlessly pursuing a world where no one dies of Amyotrophic Lateral Sclerosis (ALS). Founded in 2013 by Dan Doctoroff, Tom Maniatis, and other key figures, the organization is committed to accelerating the discovery of effective treatments and, ultimately, a cure for ALS. Target ALS achieves this by fostering unprecedented collaboration between academic and industry researchers, funding innovative high-risk, high-reward research projects, and providing essential tools and resources like novel disease models and biomarker validation to the scientific community. Their unique model emphasizes speed, innovation, and a patient-centric approach, aiming to significantly shorten the timeline from scientific discovery to clinical therapies for individuals affected by ALS.
The New York headquarters serves as the central operational base for Target ALS, coordinating global research funding, strategic partnerships, program management, fundraising, communications, and administrative functions to advance its mission against ALS.
The headquarters is strategically located in Manhattan, providing accessibility and connectivity. While not architecturally unique, the office space is modern and designed to foster a collaborative and efficient work environment for its team dedicated to combating ALS.
The work culture at Target ALS headquarters is characterized by a strong sense of urgency, mission-driven dedication, and intensive collaboration. Team members are passionate about making a tangible impact in the fight against ALS, fostering an innovative, agile, and results-oriented environment.
The headquarters is pivotal as the command center for orchestrating Target ALS's comprehensive strategy, managing a diverse portfolio of research grants, and connecting a global network of scientists, clinicians, academic institutions, and industry partners focused on conquering ALS.
While headquartered in New York, Target ALS has a significant global impact. It funds and collaborates with leading ALS researchers, academic institutions, and biopharmaceutical companies across North America, Europe, and other key international regions. Their initiatives support international pre-competitive research consortia, facilitate global data sharing (e.g., through the Target ALS Genomics Core), and promote the development of universally relevant disease models and therapeutic strategies to combat ALS worldwide. They actively foster a global ecosystem for ALS research.
381 Park Avenue South, Suite 618
New York
NY
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Target ALS' leadership includes:
Target ALS has been backed by several prominent investors over the years, including:
In the past year, Target ALS significantly strengthened its scientific leadership with the appointment of Dr. Saliha Al-Haydari as Chief Scientific Officer. No major publicly announced executive departures have been noted during this period.
Discover the tools Target ALS uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Target ALS typically utilizes a common professional email format. The most frequently observed structure is the employee's first initial followed by their last name.
[first_initial][last]@targetals.org
Format
mraisinghani@targetals.org
Example
85%
Success rate
Target ALS Website • May 21, 2024
Target ALS revealed its Spring 2024 grant awards, allocating more than $11 million to support 29 pioneering research projects. This significant funding aims to drive the discovery of new therapeutic targets, biomarkers, and treatment approaches for ALS, fostering collaboration across academic and industry labs....more
Target ALS Website / Event News • May 3, 2024
Target ALS hosted its 2024 Annual Meeting from May 1-3, bringing together leading researchers, industry partners, clinicians, and patient advocates. The event focused on sharing the latest advancements in ALS research, fostering collaborations, and strategizing future directions to accelerate the development of effective treatments for ALS....more
Target ALS Website • September 7, 2023
Target ALS announced the appointment of Saliha M. G. S. Al-Haydari, Ph.D., as its new Chief Scientific Officer. Dr. Al-Haydari will lead the organization's scientific vision and research initiatives, leveraging her extensive experience in translational neuroscience and drug discovery to accelerate the path towards effective ALS treatments....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Target ALS, are just a search away.